A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Renal Cell Carcinoma

In brief

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Key facts

Study ID: NCT03592472
Run by: Xynomic Pharmaceuticals, Inc.
People needed: 413
Starts: 2018-07-17
Expected to finish: 2028-06-30
Last updated by the study team: 2025-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

To be enrolled in the study, patients will be required to meet all of the following criteria:
Patients aged ≥ 18 years at time of study entry.
Patients have histologically confirmed RCC with clear cell component.
Patients have locally advanced and unresectable or metastatic disease.
Measurable disease as assessed only by the investigator (not verified by IRC) according to RECIST version 1.1.
Patients must not have had any prior vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor treatment in either (neo)adjuvant or locally advanced/metastatic setting. Up to 1 line of prior cytokine or immune checkpoint inhibitor treatment is allowed in either the (neo)adjuvant or metastatic setting provided screening scans indicate progressive disease (PD) during or following completion of treatment.
Patients have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Patients have adequate baseline organ function.
Patients have adequate baseline hematologic function
Patient must be at least 2 weeks from last systemic treatment or dose of radiation prior to date of randomization.

You may not qualify if…

Patients who meet any of the following criteria at Screening will not be enrolled in the study:
Has persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
Has untreated central nervous system (CNS) metastases. Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated.
Has an additional malignancy requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
Has a QTcF interval > 480 msec.
New York Heart Association Class III or IV congestive heart failure.
Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

Where it is running

Beijing Cancer Hospital — Beijing, China (enrolling)
University of California Davis Comprehensive Cancer Center — Sacramento, California, United States
UCSF Helen Diller Family Comphrensive Cancer Center - Hemato — San Francisco, California, United States
Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky, United States
Ochsner Clinic Foundation — New Orleans, Louisiana, United States
GU Research Network/Urology Cancer Center — Omaha, Nebraska, United States
Nebraska Cancer Specialists — Omaha, Nebraska, United States
Northwell Health/Monter Cancer Center — Lake Success, New York, United States
Mainstreet Physicans Care — Rochester, New York, United States
Precision Cancer Research/Dayton Physicians Network - Treatment — Kettering, Ohio, United States
Oregon Health and Science University — Portland, Oregon, United States
St. Luke's Hospital — Easton, Pennsylvania, United States
HOPE Cancer Center of East Texas — Tyler, Texas, United States
Medical Oncology Associates, PS (dba Summit Cancer Centers) — Spokane, Washington, United States
Zhongshan Hospital Affiliated to Fudan University — Shanghai, China
Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica — Candiolo, Italy
A.O. Cannizzaro_UOS Oncologia Medica — Catania, Italy
IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica — Meldola (FC), Italy
Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale — Milan, Italy
Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica — Naples, Italy
Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica — Novara, Italy
Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica — Pavia, Italy
Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria — Pisa, Italy
Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica — Roma, Italy
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny — Brzozów, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.